CD133, OCT4, and NANOG in ulcerative colitis-associated colorectal cancer

Yasuda,Hiromi; Tanaka,Koji; Okita,Yoshiki; Araki,Toshimitsu; Saigusa,Susumu; Toiyama,Yuji; Yokoe,Takeshi; Yoshiyama,Shigeyuki; Kawamoto,Aya; Inoue,Yasuhiro; Miki,Chikao; Kusunoki,Masato

doi:10.3892/ol.2011.415

CD133, OCT4, and NANOG in ulcerative colitis-associated colorectal cancer

Authors:
- Hiromi Yasuda
- Koji Tanaka
- Yoshiki Okita
- Toshimitsu Araki
- Susumu Saigusa
- Yuji Toiyama
- Takeshi Yokoe
- Shigeyuki Yoshiyama
- Aya Kawamoto
- Yasuhiro Inoue
- Chikao Miki
- Masato Kusunoki
View Affiliations

Affiliations: Department of Gastrointestinal and Pediatric Surgery, and Innovative Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Mie 514-8507, Japan
Published online on: September 6, 2011 https://doi.org/10.3892/ol.2011.415
Pages: 1065-1071

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Stem cells are thought to contribute to tissue regeneration as well as carcinogenesis. Ulcerative colitis‑associated colorectal cancer (UC-CRC) has shown distinct characteristics compared with those of sporadic CRC. The aim of this study was to evaluate the expression of stem cell markers CD133, OCT4 and NANOG in UC-CRC and the inflamed colonic epithelium of UC patients. Total RNAs of UC-CRC (n=6), inflamed colonic epithelium (n=24), sporadic CRC (n=37) and adjacent normal colonic epithelium (n=37) were isolated from formalin-fixed, paraffin-embedded specimens using microdissection techniques in order to purify colonic epithelial cells. Relative mRNA levels of CD133 (PROM), OCT4 (POU5F1) and NANOG were measured using real-time reverse transcription polymerase chain reaction. Three stem cell markers were also investigated immunohistochemically. PROM, POU5F1 and NANOG levels were found to be significantly lower in UC-CRC than in inflamed colonic epithelium of UC patients. By contrast, sporadic CRC showed a significantly higher expression of PROM, POU5F1 and NANOG compared with adjacent normal colonic epithelium. POU5F1 and NANOG levels were significantly lower in UC-CRC than in sporadic CRC. PROM and NANOG levels in inflamed colonic epithelium were significantly higher among younger UC patients (P<0.05). Longer disease duration was significantly associated with lower PROM expression (P=0.0117). No significant difference was found in PROM levels between UC-CRC and inflamed colonic epithelium in patients with longer disease duration. UC-CRC showed different expression profiles of stem cell markers compared with sporadic CRC. Decreases in PROM expression of inflamed colonic epithelium may identify UC patients at high risk for the development of UC-CRC.

View Figures

View References

1	Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI
2	Zisman TL and Rubin DT: Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 14:2662–2669. 2008. View Article : Google Scholar : PubMed/NCBI
3	Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C and Ullman T: Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 133:1099–1105. 2007. View Article : Google Scholar : PubMed/NCBI
4	Watanabe T, Kobunai T, Toda E, et al: Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clin Cancer Res. 13:415–420. 2007. View Article : Google Scholar : PubMed/NCBI
5	Fujii S, Tominaga K, Kitajima K, et al: Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut. 54:1287–1292. 2005. View Article : Google Scholar : PubMed/NCBI
6	Nishikawa M, Oshitani N, Matsumoto T, Nishigami T, Arakawa T and Inoue M: Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative colitis. Br J Cancer. 93:331–337. 2005. View Article : Google Scholar : PubMed/NCBI
7	Bartsch H and Nair J: Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg. 391:499–510. 2006. View Article : Google Scholar : PubMed/NCBI
8	Boman BM and Huang E: Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol. 26:2828–2838. 2008. View Article : Google Scholar : PubMed/NCBI
9	Vermeulen L, Sprick MR, Kemper K, Stassi G and Medema JP: Cancer stem cells – old concepts, new insights. Cell Death Differ. 15:947–958. 2008.
10	Shipitsin M and Polyak K: The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest. 88:459–463. 2008. View Article : Google Scholar : PubMed/NCBI
11	Liang J, Wan M, Zhang Y, et al: Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol. 10:731–739. 2008. View Article : Google Scholar : PubMed/NCBI
12	Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK and Trosko JE: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis. 26:495–502. 2005.PubMed/NCBI
13	Wang J, Levasseur DN and Orkin SH: Requirement of Nanog dimerization for stem cell self-renewal and pluripotency. Proc Natl Acad Sci USA. 105:6326–6331. 2008. View Article : Google Scholar : PubMed/NCBI
14	Horst D, Kriegl L, Engel J, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 99:1285–1289. 2008. View Article : Google Scholar : PubMed/NCBI
15	Bijwaard KE, Aguilera NS, Monczak Y, Trudel M, Taubenberger JK and Lichy JH: Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem. 47:195–201. 2001.PubMed/NCBI
16	Lanzoni G, Roda G, Belluzzi A, Roda E and Bagnara GP: Inflammatory bowel disease: Moving toward a stem cell-based therapy. World J Gastroenterol. 14:4616–4626. 2008. View Article : Google Scholar : PubMed/NCBI
17	Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
18	O’Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106–110. 2007.PubMed/NCBI
19	Ieta K, Tanaka F, Haraguchi N, et al: Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 15:638–648. 2008. View Article : Google Scholar : PubMed/NCBI
20	Brentnall TA, Crispin DA, Rabinovitch PS, et al: Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 107:369–378. 1994.PubMed/NCBI
21	Tarmin L, Yin J, Harpaz N, et al: Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 55:2035–2038. 1995.PubMed/NCBI
22	Chaubert P, Benhattar J, Saraga E and Costa J: K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. Am J Pathol. 144:767–775. 1994.PubMed/NCBI
23	Farrell RJ and Peppercorn MA: Ulcerative colitis. Lancet. 359:331–340. 2002. View Article : Google Scholar : PubMed/NCBI
24	Matsumoto T, Nakamura S, Jo Y, Yao T and Iida M: Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol. 98:1827–1833. 2003. View Article : Google Scholar : PubMed/NCBI
25	Rutter MD, Saunders BP, Schofield G, Forbes A, Price AB and Talbot IC: Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 53:56–260. 2004. View Article : Google Scholar : PubMed/NCBI